Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Certara Inc (CERT)

Certara Inc (CERT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,634,333
  • Shares Outstanding, K 161,018
  • Annual Sales, $ 385,150 K
  • Annual Income, $ -12,050 K
  • EBIT $ 52 M
  • EBITDA $ 121 M
  • 60-Month Beta 1.60
  • Price/Sales 4.31
  • Price/Cash Flow 14.34
  • Price/Book 1.57

Options Overview Details

View History
  • Implied Volatility 51.73% ( -15.44%)
  • Historical Volatility 36.97%
  • IV Percentile 11%
  • IV Rank 21.54%
  • IV High 197.98% on 03/13/25
  • IV Low 11.58% on 09/23/24
  • Put/Call Vol Ratio 0.42
  • Today's Volume 71
  • Volume Avg (30-Day) 30
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 1,304
  • Open Int (30-Day) 1,685

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.05
  • Number of Estimates 3
  • High Estimate 0.06
  • Low Estimate 0.05
  • Prior Year 0.06
  • Growth Rate Est. (year over year) -16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.92 +2.02%
on 03/27/25
12.27 -17.52%
on 03/04/25
-2.28 (-18.39%)
since 02/27/25
3-Month
9.92 +2.02%
on 03/27/25
15.69 -35.50%
on 02/14/25
-0.57 (-5.33%)
since 12/27/24
52-Week
9.41 +7.55%
on 11/21/24
19.18 -47.23%
on 04/09/24
-7.50 (-42.57%)
since 03/27/24

Most Recent Stories

More News
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

CERT : 10.12 (-0.30%)
Certara Reports Fourth Quarter 2024 Financial Results

CERT : 10.12 (-0.30%)
Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

CERT : 10.12 (-0.30%)
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

CERT : 10.12 (-0.30%)
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

CERT : 10.12 (-0.30%)
Certara, Inc. Celebrates Over 100 Publications and Inclusion of 12 Scientists in Stanford/Elsevier's Top 2% of Cited Researchers in 2024

Certara celebrates over 100 publications in 2024 and 12 scientists recognized on Stanford/Elsevier's top 2% cited researchers list.Quiver AI SummaryCertara, Inc., a leader in model-informed drug development,...

CERT : 10.12 (-0.30%)
Certara Showcases 2024 Research Wins With Over 100 Papers Published

CERT : 10.12 (-0.30%)
Certara Reports Third Quarter 2024 Financial Results

CERT : 10.12 (-0.30%)
Certara to Participate in the Stephens Annual Investment Conference

CERT : 10.12 (-0.30%)
Certara Appoints John Reynders as New Independent Board Member

CERT : 10.12 (-0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Certara Inc. provides medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Certara Inc. is based in NJ, United States.

See More

Key Turning Points

3rd Resistance Point 10.55
2nd Resistance Point 10.39
1st Resistance Point 10.25
Last Price 10.12
1st Support Level 9.95
2nd Support Level 9.79
3rd Support Level 9.65

See More

52-Week High 19.18
Fibonacci 61.8% 15.45
Fibonacci 50% 14.29
Fibonacci 38.2% 13.14
Last Price 10.12
52-Week Low 9.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar